Macupatide

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

1

Maridebart Cafraglutide

Amgen

Phase 3

72

NNC0487-0111

Novo Nordisk

Phase 3

113

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

14

Zenagamtide

Novo Nordisk

Phase 3

35

Berobenatide

Pfizer

Phase 3

36

Ribupatide

KKailera

Phase 3

37

Elecoglipron

AstraZeneca

Phase 3

18

PF-08653944

Pfizer

Phase 3

59

Survodutide

Boehringer Ingelheim

Phase 3

210

Avapro

Sanofi

Preclinical

1Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Obesity3 trials

A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes

Recruiting·Eli Lilly·Phase 2·NCT07215559·200 enrolled

A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macupatide Monotherapy, and Macupatide in Combination With Eloralintide, in Japanese Participants With Obesity or Overweight Without Type 2 Diabetes.

Not yet recruiting·Eli Lilly·Phase 1·NCT07765511·60 enrolled

A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

Recruiting·Eli Lilly·Phase 2·NCT07589608·400 enrolled

Details

Drug Info

Related News